Pulmonary hypertension — classification & work-up
WHO groups 1-5 · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Pulmonary hypertension is defined haemodynamically (mean pulmonary artery pressure >20 mmHg) and classified into five groups with different causes and treatments. Distinguishing pre-capillary (arterial, lung, thromboembolic) from post-capillary (left heart) disease is essential before any targeted therapy.
Red flags
- Syncope or presyncope
- Signs of right heart failure (ascites, oedema, raised JVP)
- Rapid functional decline
- Hypotension / low cardiac output
Assessment
Differential diagnosis
- Group 1 pulmonary arterial hypertension
- Group 2 PH due to left heart disease
- Group 3 PH due to lung disease/hypoxia
- Group 4 chronic thromboembolic PH
- Group 5 multifactorial/unclear mechanisms
Investigations
- Transthoracic echocardiography (estimated systolic PAP, RV size/function)
- ECG and NT-proBNP
- V/Q scan to exclude chronic thromboembolic disease
- Pulmonary function tests and HRCT for lung disease
- Right heart catheterisation (confirm mPAP, wedge pressure, pulmonary vascular resistance, vasoreactivity)
- Connective-tissue, HIV, liver and congenital-heart work-up for group 1
Management
- Confirm suspicion with echocardiography and assess right ventricular function
- Systematically exclude left heart disease and lung disease as predominant causes
- Perform a V/Q scan to detect chronic thromboembolic disease
- Refer suspected pre-capillary or group 1/4 disease to an expert pulmonary hypertension centre
- Confirm the diagnosis and group with right heart catheterisation
- Perform acute vasoreactivity testing in idiopathic/heritable PAH
- Treat the underlying cause in group 2 (heart) and group 3 (lung/hypoxia) rather than giving PAH drugs
- Initiate group-1 targeted combination therapy risk-stratified at an expert centre
- Refer group-4 disease for endarterectomy/angioplasty assessment
- Provide supportive care (oxygen, diuretics, rehabilitation, anticoagulation where indicated) and structured follow-up
Drugs & doses
Group 1: combination endothelin-receptor antagonist (e.g. ambrisentan 10 mg PO daily) + PDE5 inhibitor (e.g. tadalafil 40 mg PO daily)
Prostacyclin pathway agents (e.g. selexipag, IV/SC treprostinil, epoprostenol) for higher risk
Diuretics (furosemide) for right heart failure
Oxygen for hypoxaemic group 3 disease; avoid PAH drugs in uncomplicated group 2/3
Disposition
Expert pulmonary hypertension centre for groups 1 and 4; treat underlying disease for groups 2, 3 and 5.
Complications & pitfalls
- Progressive right heart failure
- Sudden cardiac death
- Arrhythmia
- Haemoptysis
Exam pearls
- Do not treat group 2 (left heart) or uncomplicated group 3 PH with PAH-specific vasodilators — risk of harm
- Right heart catheterisation is mandatory to confirm and classify before targeted therapy
- A V/Q scan is essential to avoid missing curable CTEPH
- Only a minority of idiopathic PAH are vasoreactive and suitable for calcium-channel blockers
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.